Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
11:30am, Monday, 15'th Jun 2026
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
Dividend Safety Check: FNDF and International Large-Cap Dividend Income
10:00am, Saturday, 13'th Jun 2026
The Schwab Fundamental International Equity ETF (NYSEARCA:FNDF) pays semi-annual distributions sourced from a basket of developed-market dividend payers outside the United States, and at roughly $54 a
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
05:36am, Friday, 12'th Jun 2026
Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido® (remibrutinib) met it
Novartis says rare muscle disease drug shows promise in early trial
05:41pm, Thursday, 11'th Jun 2026
Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of gene
Novartis Reports Positive Data for Neuromuscular Disorder Drug
02:26pm, Thursday, 11'th Jun 2026
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
02:26pm, Thursday, 11'th Jun 2026
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
09:14am, Thursday, 11'th Jun 2026
Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy del-brax met both its primary and key secondary endpoints in patients
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous resul
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
07:00am, Wednesday, 10'th Jun 2026
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
03:00am, Monday, 08'th Jun 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical t
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
01:05pm, Friday, 05'th Jun 2026
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
06:15am, Thursday, 04'th Jun 2026
Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgA
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
11:30am, Wednesday, 03'rd Jun 2026
Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustai
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
05:12pm, Tuesday, 02'nd Jun 2026
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
